Infection and Immunity, November 1994, p. 4955-4961, Vol. 62, No. 11
0019-9567/1994/$04.00+0 DOI:
Fusions of anthrax toxin lethal factor with shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells.
N Arora and
S H Leppla
Laboratory of Microbial Ecology, National Institute of Dental Research, Bethesda, Maryland 20892.
ABSTRACT
To investigate the ability of anthrax toxin lethal factor (LF) to translocate foreign proteins into the cytosol of eukaryotic cells and to characterize the structural requirements of this process, fusion proteins containing a portion of LF and the catalytic domains of either diphtheria toxin or Shiga toxin were constructed. Previous work showed that residues 1 to 254 of anthrax toxin lethal factor (LF1-254) are sufficient for binding to the protective antigen component of the toxin and that portions of Pseudomonas exotoxin A fused to LF1-254 are efficiently translocated to the cytosol of eukaryotic cells (N. Arora and S. H. Leppla, J. Biol. Chem. 268:3334-3341, 1993). In this study, it was found that fusion proteins containing the ADP-ribosylation domain of diphtheria toxin fused at either the amino end or the carboxyl end of LF1-254 are highly toxic to Chinese hamster ovary (CHO) cells, indicating that translocation does not strictly require that the amino terminus of LF be free. A fusion protein containing the ribosome-inactivating A1 subunit of Shiga toxin fused to the carboxyl terminus of LF1-254 was also highly toxic for CHO cells. All fusion proteins were toxic only when administered with the anthrax toxin protective antigen component. The data show that the combination of protective antigen and LF fusion proteins can efficiently import polypeptides from diverse bacterial sources to the cytosol of eukaryotic cells and that LF fusion proteins may have the passenger polypeptides fused at either the amino terminus or the carboxyl terminus of LF1-254. These LF fusion proteins could potentially be used as components of a therapeutic agent when the destruction of certain types of cells is desired (e.g., in treating cancer).
Infection and Immunity, November 1994, p. 4955-4961, Vol. 62, No. 11
0019-9567/1994/$04.00+0 DOI:
This article has been cited by other articles:
-
Tamayo, A. G., Bharti, A., Trujillo, C., Harrison, R., Murphy, J. R.
(2008). COPI coatomer complex proteins facilitate the translocation of anthrax lethal factor across vesicular membranes in vitro. Proc. Natl. Acad. Sci. USA
105: 5254-5259
[Abstract]
[Full Text]
-
Moayeri, M., Wiggins, J. F., Lindeman, R. E., Leppla, S. H.
(2006). Cisplatin inhibition of anthrax lethal toxin.. Antimicrob. Agents Chemother.
50: 2658-2665
[Abstract]
[Full Text]
-
Ratts, R., Trujillo, C., Bharti, A., vanderSpek, J., Harrison, R., Murphy, J. R.
(2005). A conserved motif in transmembrane helix 1 of diphtheria toxin mediates catalytic domain delivery to the cytosol. Proc. Natl. Acad. Sci. USA
102: 15635-15640
[Abstract]
[Full Text]
-
Zhang, S., Finkelstein, A., Collier, R. J.
(2004). Evidence that translocation of anthrax toxin's lethal factor is initiated by entry of its N terminus into the protective antigen channel. Proc. Natl. Acad. Sci. USA
101: 16756-16761
[Abstract]
[Full Text]
-
Barth, H., Aktories, K., Popoff, M. R., Stiles, B. G.
(2004). Binary Bacterial Toxins: Biochemistry, Biology, and Applications of Common Clostridium and Bacillus Proteins. Microbiol. Mol. Biol. Rev.
68: 373-402
[Abstract]
[Full Text]
-
Spyres, L. M., Daniel, J., Hensley, A., Qa'Dan, M., Ortiz-Leduc, W., Ballard, J. D.
(2003). Mutational Analysis of the Enzymatic Domain of Clostridium difficile Toxin B Reveals Novel Inhibitors of the Wild-Type Toxin. Infect. Immun.
71: 3294-3301
[Abstract]
[Full Text]
-
Liu, S., Leppla, S. H.
(2003). Cell Surface Tumor Endothelium Marker 8 Cytoplasmic Tail-independent Anthrax Toxin Binding, Proteolytic Processing, Oligomer Formation, and Internalization. J. Biol. Chem.
278: 5227-5234
[Abstract]
[Full Text]
-
Liu, S., Aaronson, H., Mitola, D. J., Leppla, S. H., Bugge, T. H.
(2003). Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proc. Natl. Acad. Sci. USA
100: 657-662
[Abstract]
[Full Text]
-
Hung, C.-F., Cheng, W.-F., Hsu, K.-F., Chai, C.-Y., He, L., Ling, M., Wu, T-C.
(2001). Cancer Immunotherapy Using a DNA Vaccine Encoding the Translocation Domain of a Bacterial Toxin Linked to a Tumor Antigen. Cancer Res.
61: 3698-3703
[Abstract]
[Full Text]
-
Brossier, F., Weber-Levy, M., Mock, M., Sirard, J.-C.
(2000). Protective Antigen-Mediated Antibody Response against a Heterologous Protein Produced In Vivo by Bacillus anthracis. Infect. Immun.
68: 5731-5734
[Abstract]
[Full Text]
-
Singh, Y., Klimpel, K. R., Goel, S., Swain, P. K., Leppla, S. H.
(1999). Oligomerization of Anthrax Toxin Protective Antigen and Binding of Lethal Factor during Endocytic Uptake into Mammalian Cells. Infect. Immun.
67: 1853-1859
[Abstract]
[Full Text]
-
Arora, N., Masood, R., Zheng, T., Cai, J., Smith, D. L., Gill, P. S.
(1999). Vascular Endothelial Growth Factor Chimeric Toxin Is Highly Active against Endothelial Cells. Cancer Res.
59: 183-188
[Abstract]
[Full Text]
-
Ballard, J. D., Collier, R. J., Starnbach, M. N.
(1998). Anthrax Toxin as a Molecular Tool for Stimulation of Cytotoxic T Lymphocytes: Disulfide-Linked Epitopes, Multiple Injections, and Role of CD4+ Cells. Infect. Immun.
66: 4696-4699
[Abstract]
[Full Text]
-
Gupta, P., Batra, S., Chopra, A. P., Singh, Y., Bhatnagar, R.
(1998). Expression and Purification of the Recombinant Lethal Factor of Bacillus anthracis. Infect. Immun.
66: 862-865
[Abstract]
[Full Text]
-
Goletz, T. J., Klimpel, K. R., Arora, N., Leppla, S. H., Keith, J. M., Berzofsky, J. A.
(1997). Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. Proc. Natl. Acad. Sci. USA
94: 12059-12064
[Abstract]
[Full Text]
Copyright © 1994 by the American Society for Microbiology. All rights reserved.